ubenimex

Alternative oncology
A competitive protease-inhibiting peptide isolated from the supernatant broth of cultured Streptomyces olivoreticuli that inhibits aminopeptidases B and N and leukotriene A4 hydrolase. Ubenimex stimulates the immune system, activates macrophages, increases production and secretion of IL-1 and IL-2, and stimulates T cells and haematopoiesis. It is in clinical trials for acute myeloid leukaemia and may be effective in treating various cancers, including Hodgkin lymphoma, leukaemia, melanoma, and cancers of the bladder, oesophagus, head and neck, lung and stomach.

Mentioned in ?

References in periodicals archive ?

M2 PHARMA-January 19, 2018-Eiger BioPharmaceuticals to Discontinue Development of Ubenimex in PAH

No safety signals attributed to ubenimex were identified in the preliminary analysis.

Eiger will continue to develop ubenimex for lymphedema based on its distinct mechanism of action impacting lymphangiogenesis as published in Science Translational Medicine (Tian et al, May 2017).

Eiger BioPharmaceuticals to Discontinue Development of Ubenimex in PAH

Abe, "Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines," Leukemia, vol.

Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of [CD34.sup.+] Cells

The inhibition of CD 13 by the commercially available neutralizing antibody ubenimex resulted in the increase of ROS in response to chemotherapy, leading to the significant reduction in the size of tumours in subcutaneous mouse xenograft models (Fig.

(2016) A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.

The inhibition of CD13 by the commercially available neutralizing antibody ubenimex results in the increase of ROS, leading to apoptosis.

Getting to the heart of the matter in cancer: novel approaches to targeting cancer stem cells

M2 EQUITYBITES-July 20, 2016-Eiger BioPharmaceuticals doses first patient in Phase 2 LIBERTY study of Ubenimex

Eiger BioPharmaceuticals, a clinical-stage biopharmaceutical company, has dosed the first patient in the Phase 2 LIBERTY study of Ubenimex in Pulmonary Arterial Hypertension, it was reported yesterday.

The study will assess the effects of Ubenimex added to current standard of care in patients with pulmonary arterial hypertension.

Eiger BioPharmaceuticals doses first patient in Phase 2 LIBERTY study of Ubenimex

Piper Jaffray analyst Edward Tenthoff cut his price target for Eiger BioPharmaceuticals to $17 from $35 after the Phase II Liberty study of ubenimex in pulmonary arterial hypertension failed to meet the primary and secondary endpoints.

Eiger BioPharmaceuticals price target lowered to $17 from $35 at Piper Jaffray

M2 PHARMA-July 20, 2016-Eiger BioPharmaceuticals doses first patient in Phase 2 LIBERTY study of Ubenimex

Eiger BioPharmaceuticals doses first patient in Phase 2 LIBERTY study of Ubenimex